The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement

CHRO

PTHS

<p>合併後的公司計劃於 2025 年 7 月推出 ZELSUVMI™，用於治療傳染性軟疣感染。與合併的完成同時，合併後的公司完成了一項 5010 萬美元的股權私募融資</p>

Pelthos Therapeutics 完成與 Channel Therapeutics 的合併，併成功完成 5010 萬美元的私募融資